Late Outcome of a Randomized Study on Oral Magnesium for Premature Complexes

Abstract

BackgroundVentricular and supraventricular premature complexes (PC) are frequent and usually symptomatic. According to a previous study, magnesium pidolate (MgP) administration to symptomatic patients can improve the PC density and symptoms.ObjectiveTo assess the late follow-up of that clinical intervention in patients treated with MgP or placebo.MethodsIn the first phase of the study, 90 symptomatic and consecutive patients with PC were randomized (double-blind) to receive either MgP or placebo for 30 days. Monthly follow-up visits were conducted for 15 months to assess symptoms and control electrolytes. 24-hour Holter was performed twice, regardless of symptoms, or whenever symptoms were present. In the second phase of the study, relapsing patients, who had received MgP or placebo (crossing-over) in the first phase, were treated with MgP according to the same protocol.ResultsOf the 45 patients initially treated with MgP, 17 (37.8%) relapsed during the 15-month follow-up, and the relapse time varied. Relapsing patients treated again had a statistically significant reduction in the PC density of 138.25/hour (p < 0.001). The crossing-over patients reduced it by 247/hour (p < 0.001). Patients who did not relapse, had a low PC frequency (3 PC/hour). Retreated patients had a 76.5% improvement in symptom, and crossing-over patients, 71.4%.ConclusionSome patients on MgP had relapse of symptoms and PC, indicating that MgP is neither a definitive nor a curative treatment for late follow-up. However, improvement in the PC frequency and symptoms was observed in the second phase of treatment, similar to the response in the first phase of treatment.

The Role of Hypomagnesemia in Cardiac Arrhythmias: A Clinical Perspective

“…The number of premature atrial and ventricular contractions increases with age, with a prevalence of 50% in the general population [ 73 ]. A low magnesium level has been suggested to increase the number of premature atrial and ventricular contractions in healthy subjects.…”

“…A pilot randomised trial showed no reduction in the number of PACs after the administration of 400 mg of magnesium daily over 12 weeks, in 59 adults, compared to placebo [ 75 ]. On the other hand, a recent two-phased randomised study on the effect of magnesium supplementation for PAC and PVC showed that even if magnesium is not a curative treatment for arrhythmia, it was associated with a reduction in premature complexes and symptoms in both phases [ 73 ].…”

Магнийсодержащие Лекарственные Препараты: От Клинической Фармакологии До Фармацевтической Помощи (2-Я Часть)

“…Разгружает ишемический левый желудочек посредством снижения системного давления в аорте [23]. Улучшение частоты и проявления желудочковых и наджелудочковых преждевременных комплексов [24] Магния L-аспартат Оказывает стимулирующее действие на нервную систему [25]. Эффективно и быстро компенсирует дефицит магния среди органических соединений магния [26] Магния сульфат…”

“…It does not affect the reduction of the pain crisis, the length of hospital stay and changes in the quality of life in the treatment of sickle cell anemia [21]. The drug can be considered a potential therapeutic strategy for the treatment of sickle cell anemia by specifically blocking potassium transport channels [22]; It unloads the ischemic left ventricle by reducing systemic pressure in the aorta [23]; improves the frequency and manifestation of ventricular and supraventricular premature complexes [24] Magnesium L-Aspartate It has a stimulating effect on the nervous system [25]; effectively and quickly compensates for magnesium deficiency among organic magnesium compounds [26] Magnesium sulfate…”